Novartis Reports Omalizumab Significantly Improved Chronic Idiopathic Urticaria Symptoms in Patients Who Failed Standard

    Novartis Reports Omalizumab Significantly Improved Chronic Idiopathic
          Urticaria Symptoms in Patients Who Failed Standard Therapy

- Phase III study published in NEJM today and to be presented tomorrow met
primary endpoint in moderate-to-severe chronic idiopathic urticaria (CIU)

- CIU can be a serious, debilitating form of hives; >50% of patients don't
achieve symptom relief with approved antihistamine doses

- Omalizumab is a biologic therapy that targets the IgE antibody; further
Phase III studies in CIU and regulatory submissions on track for 2013

PR Newswire

EAST HANOVER, N.J., Feb. 24, 2013

EAST HANOVER, N.J., Feb. 24, 2013 /PRNewswire/ --Late-breaking results from
ASTERIA II, a Phase III placebo-controlled study, showed positive results in
patients with moderate to severe chronic idiopathic urticaria (CIU), referred
to as chronic spontaneous urticaria (CSU) outside the United States, who
remained symptomatic despite treatment with approved antihistamine doses. The
data were published today in the New England Journal of Medicine and will be
presented tomorrow at the American Academy of Allergy, Asthma & Immunology
(AAAAI) annual meeting in San Antonio, Texas. Omalizumab is not indicated for

The primary endpoint was measured using a 21-point scale known as a weekly
Itch Severity Score (ISS). The study met its primary endpoint, showing that
omalizumab given at doses of 150 mg and 300 mg every four weeks led to
significant improvement from baseline at Week 12 in the mean weekly ISS from
baseline (approximately 14 in all treatment groups) by 8.1 (p=0.001) and 9.8
(p<0.001), respectively, compared to a 5.1 improvement in patients on placebo.
The omalizumab 75 mg dose group did not demonstrate statistical significance
compared to placebo for the primary endpoint. All eight pre-specified
secondary endpoints in the ASTERIA II trial were met for the 150 mg and 300 mg
doses, except for the 150 mg dose that did not show a significant difference
from placebo in the proportion of angioedema-free days from Week 4 to Week 12
of therapy.

CIU is a distressing skin condition characterized by red, swollen, itchy and
sometimes painful hives on the skin, spontaneously presenting and reoccurring
for more than six weeks. At any given time, the prevalence of CIU is 0.5% to
1% worldwide. While antihistamines are used first to treat CIU, more than 50%
of patients are unable to achieve symptom relief with approved doses.

"These results indicate that omalizumab could potentially be an important
addition in the treatment of chronic idiopathic urticaria, a disease that can
have a significant impact on patients and can be challenging to manage," said
Tim Wright, Global Head of Development, Novartis Pharmaceuticals. "We are
committed to helping patients with this disease and look forward to receiving
further results from ongoing longer-term clinical trials."

ASTERIA II is the first Phase III data to be presented from a clinical trial
program in CIU, which also includes two additional studies investigating the
efficacy and safety profile of omalizumab over 24 weeks treatment duration.
Novartis regulatory submissions are on track for 2013.

"These results are encouraging news for appropriate patients whose CIU is
unresponsive to antihistamines," said study co-lead investigator, Thomas
Casale, MD, Chief of Allergy & Immunology at Creighton University Medical
Center and Professor of Medicine and Medical Microbiology at Creighton
University, Omaha, NE. "New and effective therapeutic strategies for CIU are
necessary as treatment options are limited for these patients."

Study Details
ASTERIA II was a global, multi-center, randomized, double-blind study that
evaluated the efficacy and safety profile of omalizumab compared to placebo
and involved 323 patients aged between 12 and 75 with a diagnosis of moderate
to severe CIU for at least six months. Patients were required to have the
presence of itch and hives for at least eight consecutive weeks at any time
prior to enrollment despite use of approved doses of H1 antihistamine
treatment. Patients were randomized to omalizumab 75 mg, 150 mg or 300 mg or
placebo, given subcutaneously every four weeks, for a total of three doses
within a 12-week treatment period, with a 16-week follow-up period. Patients
continued to receive stable doses of their pre-randomization H1 antihistamine.
For the primary endpoint, the omalizumab 75 mg dose group did not demonstrate
statistical significance compared to placebo. However, omalizumab 150 mg and
300 mg dose groups met the pre-specified primary endpoint and all eight
pre-specified secondary endpoints in the ASTERIA II trial, except for the 150
mg dose that did not show a significant difference from placebo in the
proportion of angioedema-free days from Week 4 to Week 12 of therapy. Patient
response, as measured by the median time to Minimally Important Difference
(MID) in itch severity score, a secondary endpoint, occurred at Week 1 (300
mg dose) and Week 2 (150 mg dose), compared to Week 4 in the placebo group.

The incidence and severity of adverse events (AEs) was similar across
treatment groups. The most frequently reported treatment-emergent adverse
events in patients taking omalizumab (>10% in any omalizumab treatment arm) in
the study (including treatment period and follow-up period) were
nasopharyngitis (nasal and throat infection or common cold), idiopathic
urticaria (hives and itching, trigger unknown) and headache. Five (6.3%)
patients experienced serious adverse events (SAEs) in the omalizumab 300 mg
dose group, compared to two (2.5%) in the placebo group. In the 150 mg and 75
mg dose groups, one patient experienced SAEs in each group (1.1% and 1.3%,
respectively). No deaths were reported during this study.

About Omalizumab
Omalizumab is not indicated for CIU.

Omalizumab is a biologic therapy unique in targeting immunoglobulin E (IgE).
Research is ongoing to understand the mechanism of action of omalizumab in CIU
and to investigate its potential impact on the drivers of CIU. Omalizumab is
approved for the treatment of moderate to severe allergic asthma under the
brand-name Xolair^® in more than 90 countries, including the US since 2003 and
the EU since 2005. In the US, Xolair is indicated for appropriate people who
are 12 years of age and older who have moderate to severe persistent allergic
asthma caused by year-round allergens in the air and are uncontrolled on
inhaled corticosteroids. Xolair helps reduce the number of asthma attacks in
people with allergic asthma who still have asthma symptoms even though they
are taking inhaled steroids. Xolair should not be used to treat other allergic
conditions. Xolair is not a rescue medicine and should not be used to treat
sudden asthma attacks. Xolair should not be used in children under 12 years of

Omalizumab is being jointly developed by Novartis and Genentech. In the US,
Xolair^® (omalizumab) for subcutaneous use in appropriate allergic asthma
patients is co-promoted by Novartis Pharmaceuticals Corporation and Genentech.

About Xolair^® (omalizumab) for subcutaneous use
Important Safety Information: Appropriate Moderate-Severe Allergic Asthma

Xolair should always be injected in a doctor's office. Patients should read
the Medication Guide before starting Xolair treatment and before each and
every treatment.

A severe allergic reaction called anaphylaxis has happened in some patients
after they received Xolair. Anaphylaxis is a life-threatening condition and
can lead to death. Patients must seek emergency medical treatment right away
if symptoms occur.

Signs and symptoms of anaphylaxis include:

  owheezing, shortness of breath, cough, chest tightness, or trouble
  olow blood pressure, dizziness, fainting, rapid or weak heartbeat, anxiety,
    or feeling of "impending doom"
  oflushing, itching, hives, or feeling warm
  oswelling of the throat or tongue, throat tightness, hoarse voice, or
    trouble swallowing

Anaphylaxis from Xolair can happen:

  oright after receiving a Xolair injection or hours later
  oafter any Xolair injection. Anaphylaxis has occurred after the first
    Xolair injection or after many Xolair injections.

A patient's healthcare provider should watch the patient for some time in the
office for signs or symptoms of anaphylaxis after injecting Xolair. If
patients have signs or symptoms of anaphylaxis, they must tell their
healthcare provider right away.

Patients must not receive Xolair if they have ever had an allergic reaction to
a Xolair injection. Patients should not use Xolair if they are allergic to any
of its ingredients.

In clinical studies, a variety of cancer types, including breast, skin,
prostate, and parotid (a type of salivary gland), were reported in more
patients who received Xolair than in patients who did not receive Xolair.

Xolair is not a rescue medicine and should not be used to treat sudden asthma

Xolair is not a substitute for the medicines patients are already taking.
Patients must not change or stop taking any of their other asthma medicines
unless their doctor tells them to do so.

Some patients on Xolair may have an abnormal increase in eosinophils (a type
of white blood cell) in the blood or tissues, sometimes causing an
inflammation of blood vessels which can lead to rash, worsening of respiratory
symptoms, heart trouble, and/or nerve pain and weakness.

Joint inflammation or pain, rash, fever, and swollen lymph nodes have been
seen in some patients taking Xolair after the first or subsequent injections.
Patients should talk to their doctor if they have experienced any of these
signs and symptoms.

In allergic asthma studies, the most commonly seen side effects occurring more
frequently in patients receiving Xolair than in patients who received placebo
(an injection with no active medicine) were joint pain, pain (general), leg
pain, tiredness (fatigue), dizziness, fracture, arm pain, itching,
inflammation of the skin, and earache.

In allergic asthma studies, the most common side effects in patients, who
either needed to stop Xolair or needed medical attention, were injection site
reaction, viral infections, upper respiratory tract infection, sinusitis,
headache, and sore throat. These side effects were seen at similar rates in
Xolair-treated patients as in patients that did not receive Xolair.

There are other possible side effects with Xolair. Patients should talk to
their doctor for more information and if they have any questions about their

Xolair has not been studied in pregnant women. Pregnant women exposed to
Xolair are encouraged to enroll in the Xolair Pregnancy Exposure Registry.
Patients can get more information by calling 1-866-4XOLAIR (1-866-496-5247) or
by speaking with their doctor.

For the full Prescribing Information, including Boxed WARNINGS and Medication
Guide for additional important safety information please log onto
or contact Christine Cascio at 862-778-8026.

The foregoing release contains forward-looking statements that can be
identified by terminology such as "to be," "will be," "to investigate,"
"potentially," "could," "committed," "look forward to," "on track,"
"potential," or similar expressions, or by express or implied discussions
regarding potential new indications or labeling for omalizumab or regarding
potential future revenues from omalizumab. You should not place undue reliance
on these statements. Such forward-looking statements reflect the current
views of management regarding future events, and involve known and unknown
risks, uncertainties and other factors that may cause actual results with
omalizumab to be materially different from any future results, performance or
achievements expressed or implied by such statements. There can be no
guarantee that omalizumab will be approved for any additional indications or
labeling in any market. Nor can there be any guarantee that omalizumab will
achieve any particular levels of revenue in the future. In particular,
management's expectations regarding omalizumab could be affected by, among
other things, unexpected clinical trial results, including unexpected new
clinical data and unexpected additional analysis of existing clinical data;
unexpected regulatory actions or delays or government regulation generally;
the company's ability to obtain or maintain patent or other proprietary
intellectual property protection; government, industry and general public
pricing pressures; competition in general; unexpected manufacturing issues;
the impact that the foregoing factors could have on the values attributed to
the Novartis Group's assets and liabilities as recorded in the Group's
consolidated balance sheet, and other risks and factors referred to in
Novartis AG's current Form 20-F on file with the US Securities and Exchange
Commission. Should one or more of these risks or uncertainties materialize, or
should underlying assumptions prove incorrect, actual results may vary
materially from those anticipated, believed, estimated or expected. Novartis
is providing the information in this press release as of this date and does
not undertake any obligation to update any forward-looking statements
contained in this press release as a result of new information, future events
or otherwise.

About Novartis
Novartis Pharmaceuticals Corporation researches, develops, manufactures and
markets innovative prescription drugs used to treat a number of diseases and
conditions, including cardiovascular, dermatological, central nervous system,
bone disease, cancer, organ transplantation, psychiatry, infectious disease
and respiratory. The company's mission is to improve people's lives by
pioneering novel healthcare solutions.

Located in East Hanover, New Jersey, Novartis Pharmaceuticals Corporation is
an affiliate of Novartis AG, which provides innovative healthcare solutions
that address the evolving needs of patients and societies. Headquartered in
Basel, Switzerland, Novartis offers a diversified portfolio to best meet these
needs: innovative medicines, eye care, cost-saving generic pharmaceuticals,
preventive vaccines and diagnostic tools, over-the-counter and animal health
products. Novartis is the only global company with leading positions in these
areas. In 2012, the Group achieved net sales of USD 56.7 billion, while R&D
throughout the Group amounted to approximately USD 9.3 billion (USD 9.1
billion excluding impairment and amortization charges). Novartis Group
companies employ approximately 128,000 full-time-equivalent associates and
operate in more than 140 countries around the world. For more information,
please visit

Novartis is on Twitter. Sign up to follow @Novartis at

Novartis Media Relations

Julie Masow
Novartis Corporation
+1 212 830 2465 (direct)
+1 862 579 8456 (mobile)

Christine Cascio
Novartis Pharmaceuticals Corporation
+1 862 778 8026 (direct)
+1 862 926 7992 (mobile)


SOURCE Novartis Pharmaceuticals Corporation

Press spacebar to pause and continue. Press esc to stop.